The GWAS variant at this locus was shown to increase the risk of schizophrenia by <10% with an odds ratio of 1.08 at the population level,8 whereas the dopamine D2 receptor has been a primary target of most antipsychotic interventions.19 Therefore, the effect size of a given DNA variant on genetic risk for psychiatric disorders does not always reflect the therapeutic value of its affected molecule or biological pathway, and the GWAS-identified risk loci could provide valuable clues. This evidence concerns the gene DRD2 and schizophrenia.